How Two PBM Quotes Can Look Identical and Perform Differently
Put two PBM quotes side by side. The discount off average wholesale price is the same, the rebate guarantees are close and the administrative fees line up. There may not be much to separate them at first glance. But those headline terms can sit on top of very different pharmacy strategies.
Formulary choices, clinical criteria and utilization all help determine what a plan ultimately pays. Similar pricing does not necessarily mean similar total spend. The challenge is not that broker’s don’t have the expertise. It is making the variables behind the quote visible enough to evaluate them. That starts with understanding what unit price does, and does not, tell you.
Why unit price only tells part of the story
There’s a reason why the focus had been on discounts, rebate guarantees and fees. They matter and they’re easy to put in a column. But they do not tell you which drugs will be dispensed, how much will be used or which members will receive coverage.
Those are questions about utilization and drug mix. Formulary strategy and clinical criteria influence which treatments are preferred, when prior authorization is required and what information is needed for approval.
Two PBMs can offer similar headline pricing and still project different total spend because the mix and volume behind that pricing are different.
Pricing matters. Utilization matters. Neither tells the full story on its own.
Lower unit cost does not always mean lower total cost
You see this every time you shop in bulk. Buy more and the price per unit usually comes down. That can be a good deal, but only if the amount you are buying makes sense. A lower unit price on more volume can still leave you with a bigger total bill.
PBM pricing can work the same way. One PBM can show a better discount while its formulary and clinical criteria drive more utilization. Another can show a less aggressive discount but produce lower total spend.
That is why the discount is only part of the conversation. The next question is: What will actually be dispensed, and why?
When a better rebate can cost more
Consider the therapies used for plaque psoriasis. Skyrizi and Yusimry have approved uses in this condition, but they are different medicines with different clinical considerations. Yusimry is a biosimilar to Humira, not to Skyrizi. [1, 2][KD1]
The point is not that one can automatically replace the other. The appropriate treatment depends on the patient and clinical judgment. The economic question is how a PBM’s formulary and clinical strategy shape the mix of therapies the plan is likely to cover.
In an illustrative comparison, a higher-cost therapy may carry a larger rebate. If more utilization flows to that therapy, an attractive rebate guarantee can coexist with higher total plan spend. The rebate number alone does not establish which strategy is less expensive.
Before comparing the rebate, understand the treatment mix behind it and the clinical reasons for that mix.
The same drug can mean different utilization
GLP-1 coverage illustrates the other side of the problem: how many members qualify under a program’s actual criteria.
Different prior-authorization requirements, treatment-history documentation or approval processes can change projected utilization. A projection based on one set of criteria should not be treated as equivalent to a projection built on another.
That is not an argument for restricting appropriate care. It is a reason to understand the actual clinical program, its member impact and the assumptions used to model it before judging the price.
The price of a claim and the number of claims are different parts of the same calculation.
The management trade-off
A richer rebate or deeper discount can sit on top of higher utilization. The quoted deal can look better as management loosens while net plan spend moves the other way.
Management also affects members. Formulary changes may require some members to change therapies and clinical programs may add review or documentation at the point of care. The type, timing and extent of that impact matter alongside the expected economics.
The point is knowing what the client is trading and whether the economics justify it, not that more management is always better.
The market optimized for what buyers measured
When a comparison emphasizes the discount and rebate, it rewards what those lines show. Formulary strategy and clinical criteria are harder to compare, but that does not make them less important.
A rebate guarantee fits in a cell. A clinical protocol does not.
A stronger evaluation makes room for both. It separates pricing differences from differences in utilization, drug mix and assumptions, so the recommendation is based on more than the best-looking headline number.
Explore the full framework in How Brokers Make PBM Recommendations That Hold Up.